Introduction: Fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN Ò ; Alimera Sciences Limited, Aldershot, UK) has been approved in the UK for the treatment of chronic diabetic macula edema, insufficiently responsive to available therapies. It is inserted into the vitreous cavity through a 25-gauge
Results: The FAc implant was successfully removed from AC in two patients and reinserted into the vitreous cavity without damage or complications either for the eye or the implant. IOL in both patients were repositioned to close the gap in posterior capsule. After 2 months, the implant remains in the vitreous cavity. This paper presents data from one of these cases. In our report, we describe a novel technique for surgical removal and repositioning. The While corneal decompensation has been described in association with anterior migration of the dexamethasone implant and Retisert Ò insert (containing 0.59 milligrams of FAc [7] ; Bausch & Lomb, Rochester, NY, USA), this did not occur in our patient. We postulate that this is as a result of prompt repositioning of the implant, the smaller size of the FAc implant compared to the dexamethasone implant (which is 0.46 mm in diameter and 6 mm in length [8] ) or a combination of both factors. However, there are reports of the drug-eluting portion of the Retisert insert (which is 1.5 mm) dislocating into the anterior chamber and causing corneal edema [9] . As non-resolving corneal edema is a potential risk [10] , prompt removal is advocated in these cases.
Of note, there was resolution of intraocular pressure back to normal limits after removal of the implant. Reports suggest that placement of steroid implants closer to the trabecular meshwork or ciliary body results in a higher incidence of raised intraocular pressure [7] .
CONCLUSION
In conclusion, we describe a case of a FAc implant dislocation and a novel technique for ease of removal from the anterior chamber of the eye. Early removal is essential to prevent corneal edema and damage from raised intraocular pressure. Caution should be employed when deciding to inject the FAc implant in the eye with posterior capsule defects and when anterior migration occurs, we recommend repositioning into the vitreous cavity with a backflush/flute needle as a straightforward technique.
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